Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival - Clinical, radiological and pathologic long-term follow-up analysis

Clinical Neuropathology

Volumn 28, Issue 1, 2009, Pages 11-20

  Sepulveda Sanchez, J M ^a   Martinez Montero, J C ^a   Diez Lobato, R ^a   Hernandez Lain, A ^a   Cabello, A ^a   Ramos, A ^a   Gonzalez Leon, P ^a   Ricoy Campo, J R ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Anaplastic oligoastrocytoma; Anaplastic oligodendroglioma; Brain tumors; Contrast enhancement; Glioma; Oligoastrocytoma; Oligodendroglioma

Indexed keywords

LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; ASTROCYTOMA; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL POPULATION; CELL PROLIFERATION; CHILD; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUROPATHOLOGY; NEURORADIOLOGY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR CELL; TUMOR CLASSIFICATION; BRAIN TUMOR; CLASSIFICATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 62849088307     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp28011     Document Type: Article

References (23)

1. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC, Bullard DE. Clinicopathologic correlation in the oligodendroglioma. Cancer. 1987; 59: 1345-1352.
2. Cairncross JG, McDonald DR. Successful chemotherapy for recurrent malignant oligodendrogliomas. Ann Neurol. 1988; 23: 360-364.
3. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Winstein AS, Nelson AF et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol. 1992; 12: 219-227.
4. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P et al. Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neuro-Oncol. 1997; 34: 61-78.
5. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy and outcome. J Neurosurg. 1993; 78: 767-775.
6. Fischbach AJ, Martz KL, Nelson JS, Griffin TW, Chang CH, Horton J et al. Long-term survival in treated anaplastic astrocytomas. A report of combined RTOG/ECOG studies. Am J Clin Oncol. 1991; 14: 365-370.
7. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S et al. Oligodendrogliomas: reproducibility and prognosis value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001; 60: 248-262.
8. Hoang-Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology. 2001; 57: 1278-1281.
9. Ino Y, Betensky RA, Zlatescy MC, Sasaki H, Macdonald DR, Stemmer-Rachamminov AO et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001; 7: 839-845.
10. Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D et al. Procarbacine, lomustine and vincristine chemotherapy for Grade IV oligoastrocytomas. Neurosurgery. 1996; 85: 602-607.
11. Kros JM, Pieterman H, van Eden CG, Avezaat CJ. Oligodendroglioma. The Rotterdam-Dijkzigt experience. Neurosurgery. 1994; 34: 959-966.
12. Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW. A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol. 1986; 19: 15-21.
13. MacDonald DR. Low-grade gliomas, mixed gliomas and oligodendrogliomas. Semin Oncol. 1994; 2: 236-248.
14. Mariani L, Deiana G, Vassella E, Fathi AR, Murtin C, Arnold M et al. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO Grade 2 gliomas treated without chemotherapy. J Clin Oncol. 2006; 24: 4758-4763.
15. Mork SJ, Halvorsen TB, Lindergaard KF, Eide GE. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol. 1986; 45: 65-78.
16. Prayson RA, Mohan DS, Song P, Suh JH. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. Ann Diagn Pathol. 2000; 4: 218-227.
17. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP, von Deimling A. Oligodendroglial tumors and mixed gliomas. In: Louis DN, Ohgaki H, Wiestler O, Cavenee WK, (eds). Pathology and genetics of tumors of the nervous system. WHO Classification of Tumors (Chapter 2). Lyon: IARC Press; 2007. p. 53-67.
18. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery. 1994; 34: 577-582.
19. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW. Grading of oligodendrogliomas. Cancer. 1983; 52: 2107-2114.
20. Tortosa A, Viñolas N, Villa S, Verger E, Gil JM, Brell M et al. Prognosis implications of clinical, radiologic and pathologic features in patients with anaplastic giomas. Cancer. 2003; 97: 1063-1071.
21. Van den Bent M, Chinot OL, Cairncross JG. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neurooncology. 2003; 5: 128-138.
22. Wilkinson JMS, Anderson JR, Holmes AE. Oligodendroglioma. An analysis of 63 cases. J Neurol Neurosurg Psychiatry. 1987; 50: 304-312.
23. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg. 1989; 71: 487-493.